Table 5.

Base-case results of cost utility analysis based on two Markov models distinguished by use of the efficacy endpoints of complete cytogenetic response at 12 months or early molecular response at 3 months; the ICERs are largely driven by cost differences because there are no clinically significant differences between the measures of effectiveness*

Treatment	Cost, $	Effectiveness, QALYs	ICER, $/ QALY
12-month complete cytogenetic response
Imatinib-first	277 401	3.87
Physician’s choice	365 774	3.97	883 730
3-month BCR/ABL1 early molecular response
Imatinib-first	281 107	3.82
Physician’s choice	366 819	3.98	535 700

* ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.